Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial

Reuters

Jun 24, 2025

Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial

Nuvalent Inc., a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced that it will present pivotal data from its global ARROS-1 Phase 1/2 clinical trial. This data pertains to zidesamtinib, a novel ROS1-selective inhibitor, tested in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer. The presentation of the study results is scheduled for June 24, 2025, at 8:00 a.m. ET during a webcast and conference call hosted by the company. Interested parties can access the event through the Nuvalent website, with a replay and slides available for 30 days post-event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16161) on June 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545447779"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545447779\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545447779?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545447779","market":"nz","top_or_hot":-1,"title":"Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nuvalent Inc., a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced that it will present pivotal data from its global ARROS-1 Phase 1/2 clinical trial. This data pertains to zidesamtinib, a novel ROS1-selective inhibitor, tested in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer. The presentation of the study results is scheduled for June 24, 2025, at 8:00 a.m. ET during a webcast and conference call hosted by the company. Interested parties can access the event through the Nuvalent website, with a replay and slides available for 30 days post-event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16161) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 04:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nuvalent Inc., a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced that it will present pivotal data from its global ARROS-1 Phase 1/2 clinical trial. This data pertains to zidesamtinib, a novel ROS1-selective inhibitor, tested in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer. The presentation of the study results is scheduled for June 24, 2025, at 8:00 a.m. ET during a webcast and conference call hosted by the company. Interested parties can access the event through the Nuvalent website, with a replay and slides available for 30 days post-event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16161) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLjxzD6:1","article_id":"2545447779","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545447779","pubTimestamp":1750710628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial. Nuvalent Inc., a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced that it will present pivotal data from its global ARROS-1 Phase 1/2 clinical trial. This data pertains to zidesamtinib, a novel ROS1-selective inhibitor, tested in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer. The presentation of the study results is scheduled for June 24, 2025, at 8:00 a.m. ET during a webcast and conference call hosted by the company. Interested parties can access the event through the Nuvalent website, with a replay and slides available for 30 days post-event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","NUVL":"Nuvalent, Inc."},"translate_title":"Nuvalent Inc.宣布即将举行网络广播，讨论ARROS-1试验中齐地沙替尼治疗晚期ROS1阳性非小细胞肺癌的关键数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVL":0.9},"content_text":"Nuvalent Inc. Announces Upcoming Webcast to Discuss Pivotal Data on Zidesamtinib for Advanced ROS1-positive NSCLC from ARROS-1 Trial\n    \n\n        Nuvalent Inc., a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced that it will present pivotal data from its global ARROS-1 Phase 1/2 clinical trial. This data pertains to zidesamtinib, a novel ROS1-selective inhibitor, tested in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer. The presentation of the study results is scheduled for June 24, 2025, at 8:00 a.m. ET during a webcast and conference call hosted by the company. Interested parties can access the event through the Nuvalent website, with a replay and slides available for 30 days post-event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE16161) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}